Published On : August 2026
Brachytherapy delivery across Latin America's brachytherapy market spans three principal dose-rate types, each associated with a distinct set of radioisotopes suited to its specific clinical delivery approach. The brachytherapy type a facility adopts largely determines which radioisotopes it must source, since High-Dose Rate delivery relies almost exclusively on Iridium-192, while Low-Dose Rate and permanent seed implant approaches draw on a different set of isotopes entirely.
Understanding this connection matters for any facility or supplier evaluating Latin America's brachytherapy landscape, since brachytherapy type and radioisotope together determine required shielding infrastructure, treatment session length and the regulatory import pathway a facility must navigate.
Latin America's regulatory environment, governed by country-specific nuclear regulatory bodies, applies differentiated import licensing and handling requirements across these radioisotopes, with Iridium-192's relatively short half-life requiring more frequent, time-sensitive resupply than longer-lived alternatives.
For a manufacturer or supplier evaluating where to invest, this connection is not merely descriptive. Radioisotope supply relationships that support HDR delivery specifically differ meaningfully from those built around permanent seed implant isotopes, and building credibility in one segment does not automatically transfer to the other.
Facilities evaluating a new brachytherapy program typically work backward from their anticipated case mix to determine which combination of type and radioisotope best fits their clinical priorities and available capital.
New market entrants, whether hospitals building a first brachytherapy program or vendors entering the region, generally find it easier to establish credibility by committing deliberately to a specific type and radioisotope combination rather than attempting to support the full range from the outset.
Ultimately, the relationship between brachytherapy type and radioisotope choice functions as a useful lens for evaluating any facility's brachytherapy program maturity, since a program's radioisotope handling sophistication tends to track closely with how broad a range of brachytherapy types it can realistically support.
High-Dose Rate (HDR) brachytherapy delivers radiation via a high-activity source through a remote afterloader over a short treatment session, typically minutes rather than hours, making it the dominant modality across Latin America given its outpatient compatibility and scheduling efficiency. HDR's dominant position also shapes the delivery systems each brachytherapy type most commonly requires, since HDR relies specifically on afterloader technology rather than permanent seed implantation.
Low-Dose Rate (LDR) brachytherapy delivers radiation continuously over a longer period, often through permanently or temporarily implanted sources, and remains clinically relevant for specific applications including prostate seed implants despite HDR's broader market dominance.
Pulse Dose Rate (PDR) brachytherapy delivers radiation in a series of short pulses designed to approximate LDR's biological effect while offering some of HDR's scheduling and staff radiation exposure advantages, representing a smaller but clinically distinct niche within the broader brachytherapy category.
Treatment session length differs considerably across these three types, with HDR sessions typically completing within a single outpatient visit while LDR implants may remain in place for extended periods requiring inpatient monitoring.
Facility infrastructure requirements also vary meaningfully, with HDR requiring dedicated shielded treatment rooms and remote afterloader equipment, while LDR and PDR approaches carry somewhat different shielding and monitoring infrastructure needs specific to their delivery method.
Adoption patterns across Latin America favor HDR disproportionately relative to global averages, reflecting both the region's growing outpatient oncology infrastructure and the operational efficiency HDR offers facilities managing high patient volumes.
Staff radiation exposure considerations also differ across these three types, with HDR's remote afterloader design specifically engineered to minimize clinical staff proximity to the radioactive source relative to older manual LDR implantation techniques.
Cost structure varies meaningfully as well, with HDR's afterloader-centric model concentrating capital investment in reusable equipment while LDR and PDR approaches spread cost differently across implanted source materials and monitoring infrastructure.
Training pathways for radiation oncology staff also differ somewhat across these three types, with HDR's remote afterloader operation requiring a distinct skill set from the manual technique historically associated with conventional LDR implantation.
Scheduling flexibility represents a further meaningful difference across these types, with HDR's short outpatient sessions allowing facilities to treat considerably more patients per treatment room per day than LDR's extended implant duration permits.
Iridium-192 serves as the near-universal radioisotope for HDR brachytherapy delivery across Latin America, valued for its relatively high specific activity and the compact source size this allows within remote afterloader systems.
Iridium-192's comparatively short half-life, measured in months rather than years, requires facilities to maintain a regular, time-sensitive resupply relationship with isotope suppliers, making import licensing and supply chain reliability a genuine operational consideration for HDR-dependent facilities.
Supply chain stability for Iridium-192 varies meaningfully across the region, with facilities in major metropolitan hubs such as Sao Paulo, Mexico City and Bogota generally experiencing more reliable resupply than facilities outside these established demand corridors.
Given HDR's approximately 78 percent share of Latin America's brachytherapy demand, Iridium-192 supply reliability functions as a genuine bottleneck risk for the broader market, disproportionate to its role as a single radioisotope among several.
Facilities increasingly factor isotope resupply reliability into their broader procurement and vendor selection decisions, recognizing that afterloader equipment quality alone does not guarantee consistent treatment capability without dependable Iridium-192 access.
Source exchange scheduling represents a recurring operational task for HDR-equipped facilities, since Iridium-192's decay profile requires periodic replacement of the afterloader's radioactive source on a predictable, though relatively frequent, cycle.
Facilities located further from major isotope distribution hubs sometimes negotiate longer-cycle resupply contracts specifically to reduce the operational risk associated with more frequent, time-sensitive shipments.
Facilities that have standardized entirely around Iridium-192 for HDR delivery report that this concentration simplifies staff training and inventory management relative to supporting multiple radioisotope handling protocols simultaneously.
Facilities occasionally maintain a small buffer inventory of sealed sources specifically to protect against unexpected shipment delays, though this practice adds its own storage and security compliance considerations.
Iodine-125 remains a widely used radioisotope for permanent seed implant brachytherapy, particularly in prostate cancer treatment, valued for its longer half-life relative to Iridium-192 and its suitability for low-dose-rate delivery over an extended period.
Palladium-103 offers a shorter half-life alternative to Iodine-125 for permanent seed implants, delivering its radiation dose more rapidly and representing a clinically distinct option for facilities and physicians favoring a faster-delivery LDR approach.
Cesium-131 has emerged as a further permanent seed implant option, offering a half-life intermediate between Iodine-125 and Palladium-103, giving physicians an additional dose-rate profile to select from based on specific clinical circumstances.
These three radioisotopes collectively support the permanent seed implant segment of Latin America's brachytherapy market, a smaller but clinically important complement to the region's HDR-dominant overall demand pattern.
Supply and import considerations for these isotopes differ somewhat from Iridium-192 given their comparatively longer half-lives, generally allowing facilities somewhat greater scheduling flexibility around resupply timing.
Physician and facility preference among these three isotopes often reflects prior clinical training and established protocol familiarity as much as any single isotope's specific dose-rate characteristics.
Cost differences among these three isotopes also factor into facility and physician selection, with relative pricing shifting periodically based on global supply and production capacity rather than remaining fixed over time.
Facilities offering permanent seed implant brachytherapy typically maintain relationships with more than one of these isotope suppliers, giving physicians flexibility to select the specific isotope best suited to an individual patient's clinical circumstances.
Cobalt-60 represents an alternative HDR-compatible radioisotope to Iridium-192, offering a considerably longer half-life that reduces resupply frequency, though it remains less widely adopted across Latin America's HDR installed base relative to Iridium-192 specifically. Companies supplying these radioisotopes are profiled in our overview of the companies supplying these radioisotopes and delivery systems.
Ruthenium-106 serves a specific clinical niche in ophthalmic brachytherapy, used for select eye tumor treatment applications distinct from the region's broader cervical, prostate and breast cancer brachytherapy demand.
These further radioisotope options, while representing a smaller share of overall regional demand, provide facilities and physicians additional flexibility to match radioisotope selection to specific clinical circumstances beyond the region's dominant Iridium-192 and Iodine-125 pathways.
Radioisotope diversification remains a comparatively minor trend across Latin America's brachytherapy market overall, with the vast majority of both HDR and permanent seed implant demand continuing to concentrate around the region's established Iridium-192, Iodine-125 and Palladium-103 supply relationships.
Facilities considering Cobalt-60 as an Iridium-192 alternative typically weigh its reduced resupply frequency against the somewhat larger source size and shielding requirements the isotope's characteristics involve.
Clinical adoption of these alternative isotopes tends to concentrate among a smaller number of specialized facilities rather than spreading broadly across the region's overall brachytherapy installed base.
Ophthalmic brachytherapy using Ruthenium-106 typically requires close collaboration between radiation oncology and ophthalmology specialists, a multidisciplinary coordination need distinct from the region's more common cervical and prostate applications.
As Latin America's brachytherapy market matures further, gradual diversification into these additional radioisotope options may extend somewhat beyond their current niche role, though Iridium-192 is likely to retain its dominant position for the foreseeable future given HDR's continued market leadership.
Facilities weighing whether to invest in equipment compatible with these alternative isotopes typically consider their own specific patient population and referral base rather than following a general regional adoption trend
HDR delivers a high-activity radiation dose over a short session, typically minutes, through a remote afterloader, while LDR delivers radiation continuously over a longer period through implanted sources.
PDR delivers radiation in a series of short pulses designed to approximate LDR's biological effect while offering some of HDR's scheduling advantages.
Iridium-192 offers relatively high specific activity and a compact source size suited to remote afterloader systems, making it the near-universal choice for HDR delivery.
Iodine-125 seeds are used for permanent seed implant brachytherapy, particularly in prostate cancer treatment, valued for their longer half-life suited to low-dose-rate delivery.